文献速递浆细胞疾病白血病

如何治疗浆细胞白血病

How I treat plasma cell leukemia.
PubMed 文献 · Blood · 2026-01-01

浆细胞白血病(PCL)是定义于外周血循环浆细胞≥5%的超高危浆细胞恶性肿瘤,常伴髓外受累、严重血细胞减少及高危遗传学异常。自体移植、蛋白酶体抑制剂、免疫调节剂和单抗改善了历史结局,BCMA靶向治疗、GPRC5D靶向治疗和BCL-2抑制在原发性和继发性PCL中显示前景。但PCL研究不足,治疗多从排除PCL的多发性骨髓瘤试验外推,亟需专门前瞻性临床试验。

要点

  • PCL诊断标准为外周血循环浆细胞≥5%且符合多发性骨髓瘤诊断标准。
  • PCL常伴髓外受累、严重血细胞减少、高钙血症、肾功能不全及β2微球蛋白和乳酸脱氢酶显著升高。
  • BCMA靶向治疗、GPRC5D靶向治疗和BCL-2抑制在原发性及继发性PCL中显示治疗前景。

核心结论

  • PCL仍是研究不足的超高危浆细胞恶性肿瘤,治疗多从多发性骨髓瘤试验外推,亟需专门前瞻性临床试验以改善结局。

研究设计与样本

  • 本文为综述,综合当前证据并展示说明性临床病例以呈现实用治疗方法。

主要发现

  • PCL定义为外周血循环浆细胞≥5%且符合多发性骨髓瘤诊断标准,属超高危疾病。
  • PCL常见髓外受累、严重血细胞减少、高钙血症、肾功能不全和/或β2微球蛋白及乳酸脱氢酶显著升高。
  • PCL分子特征包括高危细胞遗传学异常和突变,通过黏附分子和趋化因子受体表达失调促进增殖加速、凋亡抵抗、免疫逃逸和骨髓微环境非依赖。
  • 自体干细胞移植、蛋白酶体抑制剂、免疫调节药物和单克隆抗体改善了历史结局。
  • BCMA靶向治疗(双特异性抗体和嵌合抗原受体T细胞疗法)、GPRC5D靶向治疗和BCL-2抑制在原发性及继发性PCL中显示前景。

关键数值与推荐

  • 国际骨髓瘤工作组共识定义PCL为外周血循环浆细胞≥5%且符合多发性骨髓瘤诊断标准。

临床怎么用

  • 临床可参考本综述综合的证据和说明性病例制定PCL治疗策略。
  • BCMA靶向治疗、GPRC5D靶向治疗和BCL-2抑制可用于原发性及继发性PCL的治疗考虑。

局限性

  • PCL研究不足,治疗approach主要从多发性骨髓瘤试验外推,而PCL患者在这些试验中大多被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasma cell leukemia (PCL) represents an exceptionally aggressive plasma cell malignancy defined by ≥5% circulating plasma cells in the peripheral blood of patients otherwise meeting the diagnostic criteria for multiple myeloma (MM), per the International Myeloma Working Group consensus. This ultrahigh-risk disease exhibits distinctive clinical features including frequent extramedullary involvement, severe cytopenias, hypercalcemia, renal insufficiency, and/or significantly elevated β2-microglobulin and lactate dehydrogenase levels. The molecular landscape includes high-risk cytogenetic abnormalities and mutations that promote accelerated proliferation, apoptotic resistance, immune evasion, and bone marrow microenvironmental independence through dysregulated adhesion molecule and chemokine receptor expression. Although autologous stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies improved historical outcomes, the therapeutic paradigm continues to evolve. Novel therapeutic approaches including B-cell maturation antigen-directed therapies (bispecific antibodies and chimeric antigen receptor T-cell therapy), G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted therapy, and B-cell lymphoma 2 (BCL-2) inhibition demonstrate promise in treating both primary and secondary PCL. Despite these advances, PCL remains inadequately studied, with treatment approaches predominantly extrapolated from MM trials in which patients with PCL have largely been excluded. This review synthesizes current evidence and presents illustrative clinical cases demonstrating practical treatment approaches, while highlighting critical knowledge gaps requiring dedicated prospective clinical trials to meaningfully improve outcomes in this challenging disease entity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Al Hadidi S, van Rhee F, Anderson LD, et al. How I treat plasma cell leukemia. Blood. 2026. PMID: 42066212. doi:10.1182/blood.2025032145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。